What is Neurocrine Biosciences's D&A?

Neurocrine Biosciences (NBIX) reported D&A of $7.2M in Q1 2026.

How has Neurocrine Biosciences's D&A changed year-over-year?

Neurocrine Biosciences's D&A increased by 9.1% year-over-year, from $6.6M to $7.2M.

What is the long-term trend for Neurocrine Biosciences's D&A?

Over 4 years (2021 to 2025), Neurocrine Biosciences's D&A has grown at a 24.3% compound annual growth rate (CAGR), from $10.9M to $26M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Neurocrine Biosciences NBIX D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.2%

Acadia PharmaceuticalsACAD

$271K+18.3%

Crinetics PharmaceuticalsCRNX

$1.16M+25.4%

Solid Biosciences Inc.SLDB

$395K-2.9%

MapLight Therapeutics, Inc. MPLT

$162K-2.4%

BridgeBio PharmaBBIO

$1.19M-7.6%

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$18.18B+34.3%

Enterprise value$18.37B+33.6%

P/E27.2×-11.7×

P/S5.9×+0.5×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's D&A?: Neurocrine Biosciences (NBIX) reported D&A of $7.2M in Q1 2026.
How has Neurocrine Biosciences's D&A changed year-over-year?: Neurocrine Biosciences's D&A increased by 9.1% year-over-year, from $6.6M to $7.2M.
What is the long-term trend for Neurocrine Biosciences's D&A?: Over 4 years (2021 to 2025), Neurocrine Biosciences's D&A has grown at a 24.3% compound annual growth rate (CAGR), from $10.9M to $26M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.